

PRESS RELEASE

STRATEC intends to modify its legal form to that of a European company

Birkenfeld, April 12, 2018

The Management Board and the Supervisory Board of STRATEC Biomedical AG have decided to propose the transformation of STRATEC Biomedical AG into a European company (Societas Europaea, SE), to be known in future as STRATEC SE, at the Annual General Meeting on May 30, 2018. As part of this change, the name supplement “Biomedical” will be dropped in the future.

In the opinion of the Management Board and the Supervisory Board, the planned change of legal form is in keeping with STRATEC’s identity as an internationally oriented company. The internationalization of STRATEC has further accelerated in recent years, in particular through the subsidiaries acquired and founded in other member states of the European Union, as well as through the revenue growth achieved with international customers. As of December 31, 2017, group-wide, 57% of employees are based abroad. In addition, for the fiscal year 2016, 87% of sales revenue was generated with customers outside of Germany. The transformation into an SE is therefore a consistent step which also offers the possibility of further optimizing STRATEC structures to the expected future international corporate growth.

With the transformation into an SE, the shareholders of STRATEC Biomedical AG automatically become shareholders of STRATEC SE. The rights of the shareholders will remain unchanged.

The conversion of legal form requires the approval of the shareholders. This is planned to be secured at the Annual General Meeting on May 30, 2018.

The shareholders of STRATEC Biomedical AG will receive detailed information on this planned legal form transformation with the invitation to the Annual General Meeting.

About STRATEC

STRATEC Biomedical AG (www.stratec.com) designs and manufactures fully automated analyzer systems for its partners in the fields of clinical diagnostics and biotechnology. Furthermore, the company offers sample preparation solutions, integrated laboratory software, and complex consumables for diagnostic and medical applications. STRATEC covers the entire value chain – from development to design and production through to quality assurance.

The partners market the systems, software and consumables, in general together with their own reagents, as system solutions to laboratories, blood banks, and research institutes around the world. STRATEC develops its products on the basis of its own patented technologies.

Shares in the company (ISIN: DE000STRA555) are traded in the Prime Standard segment of the Frankfurt Stock Exchange.

Further information is available from:

STRATEC Biomedical AG

Jan Keppeler, Investor Relations & Corporate Communications

Gewerbestr. 37, 75217 Birkenfeld

Germany

Tel: +49 7082 7916-6515

Fax: +49 7082 7916-9190

ir@stratec.com

www.stratec.com